Market research
CSTL Castle Biosciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 44
- Dividend yield
- Not available
- Beta
- 0.97
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US14843C1053
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 44
- Dividend yield
- Not available
- Beta
- 0.97
About
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CSTL discussion.
5 years, 4 months ago
Castle Biosciences, Inc is currently in a long term uptrend where the price is trading 8.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 22.2.
Castle Biosciences, Inc's total revenue sank by 1.9% to $17M since the same quarter in the previous year.
Its net income has dropped by 337.9% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 124.6% to $-1M since the same quarter in the previous year.
Based on the above factors, Castle Biosciences, Inc gets an overall score of 2/5.